Results 71 to 80 of about 1,963 (210)
RESPONSE OF RECOMBINANT HUMAN GROWTH HORMONE IN ISOLATED GROWTH HORMONE DEFICIENCY
Pakistan Armed Forces Medical Journal, 2007 Objective: To observe the response of growth hormone in isolated growth hormone deficiency. Moreover the response was compared when treatment was initiated earlier or later in childhood. Design: Quasi experimental study.
Shahid Aziz +4 more
doaj +2 more sources
Molecular Oncology, EarlyView.This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi +6 more
wiley +1 more source
The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer
Molecular Oncology, EarlyView.Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad +2 more
wiley +1 more source
JCRPEObjective: To report real-world 6- and 12-month outcomes in children with growth hormone deficiency (GHD) treated with somatrogon or somatropin, including those who transitioned from somatropin to somatrogon.
Kübra Şen Küçük +5 more
doaj +1 more source
Molecular Oncology, EarlyView.This study identifies ARHGAP5, in addition to the frequently mutated ARHGAP35, as significantly mutated in endometrial cancer. Mutations in both genes co‐occur and are associated with their correlated downregulation. Functional CRISPR studies show that both paralogs regulate similar pathways, including actin cytoskeleton organization.
Mathilde Pinault +12 more
wiley +1 more source
Journal of Education, Health and SportIntroduction and purpose Recombinant human growth hormone (rhGH) therapy has been the standard treatment for paediatric short stature for many years, and a therapeutic option for the replacement therapy of growth hormone deficiency in the post ...
Agata Kotkowiak +9 more
doaj +1 more source
Adult growth hormone deficiency: academic extravagance or real clinical entity for the internist?
Italian Journal of Medicine, 2013 The Growth Hormone (GH) continues to act lifelong: it has been described, in fact, an Adult Growth Hormone Deficiency (AGHD) syndrome, involving several organs and functions, whose clinical aspects greatly improve with the administration of human ...
Giovanni Scanelli +3 more
doaj +1 more source
Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy
Molecular Oncology, EarlyView.LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir +9 more
wiley +1 more source
FEBS Open Bio, EarlyView.RoboMic is an automated confocal microscopy pipeline for high‐throughput functional imaging in living cells. Demonstrated with fluorescence recovery after photobleaching (FRAP), it integrates AI‐driven nuclear segmentation, ROI selection, bleaching, and analysis.
Selçuk Yavuz +6 more
wiley +1 more source
Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan
Drug Design, Development and TherapyBradley S Miller,1 Jo Blair,2 Reiko Horikawa,3 Agnès Linglart,4– 7 Kevin CJ Yuen8 1Division of Pediatric Endocrinology, University of Minnesota Medical School, MHealth Fairview Masonic Children’s Hospital, Minneapolis, MN, USA; 2Department of Paediatric ...
Miller BS +4 more
doaj